August 2024

KNOW YOUR NETs Videos are Now Available

KNOW YOUR NETs 2024 was such a success! We want to share this great resource with you. The full conference recording and individual presentations are now available on our YouTube channel.

If you missed KNOW YOUR NETs, here’s a great place to start. Neuroendocrine cancer can be confusing. It can be hard to understand the differences between “NETs” and “NECs”. That's why we created a “NETs & NECs 101” video. Dr. Aman Chauhan breaks down the basics and helps us understand both types of neuroendocrine neoplasms. This is a great video to share with anyone who wants to learn more about neuroendocrine cancer.

NETWise Episode 24: Gynecologic NETs
This month, we revisit our NETWise episode on gynecologic NETs, in tribute to Dr. Michael Frumovitz from MD Anderson Cancer Center, who was an expert in these rarest neuroendocrine cancers. Dr. Frumovitz died recently. We join his family, patients, and colleagues to mourn his loss and celebrate his legacy of saving lives and improving treatment. Hear Dr. Frumovitz in this NETWise episode.

NETRF Thrivership Series: Finding Happiness and Purpose

In this month's NET Thrivership Series, we discuss the connection between happiness, purpose, enjoyment and satisfaction. Click here to explore these connections and learn how they relate to a cancer journey.

Another CAR T-cell Clinical Trial Open to Neuroendocrine Cancer Patients

A phase I CAR T-cell clinical trial targeting the molecule IL13Rα2 found on the surface of some tumors is being conducted at the University of California, Los Angeles (UCLA). CAR T-cell therapies work by engineering immune cells called T-cells to target and kill cancer cells. Read more.

Promising Advancement in Neuroendocrine Tumor Treatment: FDA Accepts Cabozantinib Application

NETRF is excited to share an important update in neuroendocrine tumor treatment. On August 6, 2024, Exelixis announced that the U.S. Food and Drug Administration has accepted their supplemental New Drug Application (sNDA) for cabozantinib (CABOMETYX®). This application aims to expand treatment options for adults with advanced, well- or moderately-differentiated pancreatic neuroendocrine tumors (pNET) and extra-pancreatic NETs (epNET). Read more.

Honoring Leadership: Drs. Shivdasani, Fisher, and Chung Named BOSA Emeritus Members

The Neuroendocrine Tumor Research Foundation extends its deepest gratitude to Ramesh Shivdasani, MD, PhD (Dana-Farber Cancer Institute), George Fisher, MD, PhD (Stanford University), and Daniel Chung, MD (Massachusetts General Hospital) for their exceptional service as members and former Chairs of the NETRF Board of Scientific Advisors (BOSA).

Read more about these distinguished individuals, who have been pivotal in shaping the direction of NETRF's scientific programs.

Fundraising and Fun to Support NETRF

We thank our NETRF community for hosting events to support vital neuroendocrine cancer research. Below is a list of upcoming fundraisers across the country.

September 14: 11th annual Hiking for Debbie at Oregon Ridge Park in Hunt Valley, Maryland, starting at the Nature Center parking lot at 9:00 a.m. This event honors the memory of Debbie Brickner.

September 20: Moonlight Walk in memory of Julie Seltzer-Firsty in Palo Alto, California.

October 19: Sheryl Strong Fundraiser at the Northridge Country Club, Fair Oaks, California, hosted by Jim Jungsten.

We will share more details and registration links about these upcoming events on our social channels and in upcoming E-Updates. If you would like to host a fundraiser for NETRF, please contact Steve Perna at Steve.Perna@netrf.org.

DONATE

Welcome Steve Perna!

NETRF welcomes Steve Perna, who has joined our team as a part-time fundraising consultant. Steve worked for more than 20 years at Tufts Medicine, in Boston, Massachusetts, where he was a director of Development. Steve brings all his experience and enthusiasm for our mission to NETRF.

Steve will meet many of our loyal donors and support the individuals and families who are organizing community fundraisers. You can contact Steve at Steve.Perna@netrf.org.

DONATE

The mission of the Neuroendocrine Tumor Research Foundation is to fund research to discover cures and more effective treatments for neuroendocrine cancers. NETRF is the largest private global funder of neuroendocrine research and the preeminent resource for expert patient education and support.

NETRF is a 501(c)(3) organization. All contributions are tax-deductible to the extent allowed by law. To learn more,
view our Audited Financial Statements and IRS Form 990.

Manage your preferences | Opt out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.

31 St. James Avenue, Suite 365
Boston, MA | 02116 US

This email was sent to .
To continue receiving our emails, add us to your address book.